Shell plc SHEL is set to release fourth-quarter results on Feb. 5. The Zacks Consensus Estimate for earnings is $1.21 per share on revenues of $68.1 billion. Let’s delve into the factors that might ...

Shell plc (NYSE:SHEL) is included among the 11 Best Energy Stocks to Buy for Dividends in 2026. Shell plc (NYSE:SHEL) is an integrated energy company with operations spanning exploration, production, ...

Global upstream oil investment is set to fall for a second straight year in 2026. Producers prioritize capital discipline amid sub-$60 oil prices, with cuts in North America and Europe offsetting ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Investors can expect a revival of speculation about a merger of global oil giants BP and ...

SLB signed a strategic collaboration agreement with Shell to develop digital and AI solutions that drive measurable performance and efficiency gains across upstream operations for the company and the ...

NEW YORK/LONDON, Dec 9 (Reuters) - Shell (SHEL.L), opens new tab is in advanced talks to buy LLOG Exploration Offshore in a deal worth more than $3 billion, two sources familiar with the matter said, ...

UK supermajor Shell is eyeing a return to Indonesia’s upstream sector, a couple of years after pulling out with the up to $650 million sale of its 35% interest in Inpex’s Masela block, which hosts the ...

TULSA, Okla.--(BUSINESS WIRE)--Williams (NYSE: WMB) announced today a series of transactions that strengthens the company’s wellhead to water strategy. First, Williams has signed definitive agreements ...

Shell and Sunlink Energies reached a final investment decision to develop the HI field to supply up to 350 million standard cubic feet of natural gas a day to Nigeria LNG. Image by ssuaphoto via ...

Upstream operations focus on oil exploration and extraction; downstream operations process crude into products. Effective energy chains require balance between upstream production and downstream ...

Biologics developers are caught in a paradox: demand for therapies is climbing, but the industry faces constant pressure to cut costs and move faster. For upstream process scientists, the challenge is ...